Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent | Zendy

Rik Rozemeijer | Zendy; Mèra Stein | Zendy; Michiel Voskuil | Zendy; Rutger van den Bor | Zendy; Peter Frambach | Zendy; Bruno Pereira | Zendy; Stefan Koudstaal | Zendy; Geert E. Leenders | Zendy; Leo Timmers | Zendy; Saskia Z.H. Rittersma | Zendy; Adriaan O. Kraaijeveld | Zendy; Pierfrancesco Agostoni | Zendy; Kit C. B. Roes | Zendy; Pieter A. Doevendans | Zendy; Pieter R. Stella | Zendy

Open Access

Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent

Author(s) -

Rik Rozemeijer,

Mèra Stein,

Michiel Voskuil,

Rutger van den Bor,

Peter Frambach,

Bruno Pereira,

Stefan Koudstaal,

Geert E. Leenders,

Leo Timmers,

Saskia Z.H. Rittersma,

Adriaan O. Kraaijeveld,

Pierfrancesco Agostoni,

Kit C. B. Roes,

Pieter A. Doevendans,

Pieter R. Stella

Publication year - 2018

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.118.037707

Subject(s) - medicine , stent , percutaneous coronary intervention , clinical endpoint , target lesion , myocardial infarction , randomized controlled trial , randomization , population , surgery , zotarolimus , cardiology , drug eluting stent , environmental health

Polymer-free amphilimus-eluting stents (PF-AES) represent a novel elution technology in the current era of drug-eluting stents. The clinical safety and efficacy of PF-AES as compared with latest-generation permanent-polymer zotarolimus-eluting stents (PP-ZES) have not yet been investigated in a large randomized trial.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research